© 2004 European Society of Cardiology
Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure
The First Department of Internal Medicine, Nippon Medical School 1-1-5 Sendagi, Tokyo, Japan
* Corresponding author. Tel.: +81-3-3822-2131; Fax: +81-3-5685-0987 E-mail address: y-seino{at}nms.ac.jp
 |
Abstract |
|---|
Background: Measurement of brain natriuretic peptide (BNP) has become a potent diagnostic aid as a means of identifying patients with systolic or diastolic dysfunction. Due to better stability in circulating blood, we reasoned that measurement of N-terminal proBNP (NT-proBNP) may be a more discerning marker for the detection and evaluation of chronic heart failure.
Methods: The relationships between plasma concentrations of NT-proBNP and BNP, and aetiology, New York Heart Association (NYHA) classification, and left ventricular ejection fraction (LVEF) were analyzed in 105 patients with chronic heart failure. Sixty-seven healthy volunteers were studied as the controls.
Results: Both NT-proBNP and BNP showed progressive increases (P<0.001) in proportion to the NYHA classification; the increment of NT-proBNP was larger than that of BNP. Elevated NT-proBNP significantly correlated with BNP (r=0.737, P<0.001). Receiver operating characteristics analysis to detect LVEF<40% showed similar values (area under the curve, AUC: NT-proBNP 0.754 vs. BNP 0.770), however, AUC to detect LVEF<50% tended to be greater for NT-proBNP than that for BNP (NT-proBNP 0.820 vs. BNP 0.794).
Conclusion: NT-proBNP may be a more discerning marker for the detection and evaluation of heart failure than BNP.
Key Words: Heart failure • Brain natriuretic peptide • Left ventricular ejection fraction • Acute coronary syndrome • Hypertensive heart disease
Received November 30, 2003; Accepted December 22, 2003
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Brune, H. A. Katus, J. Moecks, E. Spanuth, A. S. Jaffe, and E. Giannitsis N-Terminal Pro-B-Type Natriuretic Peptide Concentrations Predict the Risk of Cardiovascular Adverse Events from Antiinflammatory Drugs: A Pilot Trial Clin. Chem., July 1, 2008; 54(7): 1149 - 1157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Emdin, C. Passino, C. Prontera, M. Fontana, R. Poletti, A. Gabutti, C. Mammini, A. Giannoni, L. Zyw, G. Zucchelli, et al. Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure Clin. Chem., July 1, 2007; 53(7): 1289 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Clerico, M. Fontana, L. Zyw, C. Passino, and M. Emdin Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review Clin. Chem., May 1, 2007; 53(5): 813 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ben-Dor, M. Haim, E. Rechavia, D. Murninkas, D. Harell, A. Porter, Z. Iakobishvili, A. Battler, and D. Hasdai Serum NT-proBNP Concentrations in the Early Phase Do Not Predict the Severity of Systolic or Diastolic Left Ventricular Dysfunction Among Patients With ST-Elevation Acute Myocardial Infarction Angiology, January 1, 2007; 57(6): 686 - 693. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Cortes, M. Portoles, A. Salvador, V. Bertomeu, F. G. de Burgos, L. Martinez-Dolz, E. R. Lleti, V. Climent, A. Jordan, R. Paya, et al. Diagnostic and prognostic value of urine NT-proBNP levels in heart failure patients Eur J Heart Fail, October 1, 2006; 8(6): 621 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Costello-Boerrigter, G. Boerrigter, M. M. Redfield, R. J. Rodeheffer, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, D. M. Heublein, and J. C. Burnett Jr Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General Community: Determinants and Detection of Left Ventricular Dysfunction J. Am. Coll. Cardiol., January 17, 2006; 47(2): 345 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Richards, M. G. Nicholls, E. A. Espiner, J. G. Lainchbury, R. W. Troughton, J. Elliott, C. M. Frampton, I. G. Crozier, T. G. Yandle, R. Doughty, et al. Comparison of B-Type Natriuretic Peptides for Assessment of Cardiac Function and Prognosis in Stable Ischemic Heart Disease J. Am. Coll. Cardiol., January 3, 2006; 47(1): 52 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Talens-Visconti, M. Rivera Otero, M. J. Sancho-Tello, F. G. de Burgos, L. Martinez-Dolz, B. Sevilla, V. Climent, R. Cortes, A. Salvador, F. Sogorb, et al. Left ventricular cavity area reflects N-terminal pro-brain natriuretic peptide plasma levels in heart failure Eur J Echocardiogr, January 1, 2006; 7(1): 45 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dore, C. Houde, K.-L. Chan, A. Ducharme, P. Khairy, M. Juneau, F. Marcotte, and L.-A. Mercier Angiotensin Receptor Blockade and Exercise Capacity in Adults With Systemic Right Ventricles: A Multicenter, Randomized, Placebo-Controlled Clinical Trial Circulation, October 18, 2005; 112(16): 2411 - 2416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jefic, J. W. Lee, D. Jefic, R. T. Savoy-Moore, and H. S. Rosman Utility of B-Type Natriuretic Peptide and N-terminal Pro B-Type Natriuretic Peptide in Evaluation of Respiratory Failure in Critically Ill Patients Chest, July 1, 2005; 128(1): 288 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Reyes, G. Fores, R. Hugo Rodriguez-Abella, G. Cuerpo, J. L. Vallejo, C. Romero, and A. Pinto NT-proBNP in cardiac surgery: a new tool for the management of our patients? Interactive CardioVascular and Thoracic Surgery, June 1, 2005; 4(3): 242 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tretjak, F. Verovnik, D. Benko, and M. Kozelj Tissue Doppler velocities of mitral annulus and NT-proBNP in patients with heart failure Eur J Heart Fail, June 1, 2005; 7(4): 520 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Davutoglu, A. Celik, M. Aksoy, Y. Sezen, S. Soydinc, and N. Gunay Plasma NT-proBNP is a potential marker of disease severity and correlates with symptoms in patients with chronic rheumatic valve disease Eur J Heart Fail, June 1, 2005; 7(4): 532 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hulsmann, R. Berger, D. Mortl, O. Gore, B. Meyer, and R. Pacher Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: A direct comparison of N-terminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide Eur J Heart Fail, June 1, 2005; 7(4): 552 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-M. Hermann-Arnhof, U. Hanusch-Enserer, T. Kaestenbauer, T. Publig, A. Dunky, H. R. Rosen, R. Prager, and U. Koller N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison with Patients in Different Stages of Heart Failure Clin. Chem., January 1, 2005; 51(1): 138 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fonseca, A. G. Oliveira, T. Mota, F. Matias, H. Morais, C. Costa, F. Ceia, and on behalf of the EPICA Investigators Evaluation of the performance and concordance of clinical questionnaires for the diagnosis of heart failure in primary care Eur J Heart Fail, October 1, 2004; 6(6): 813 - 820. [Abstract] [Full Text] [PDF]
|
|